These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11739062)

  • 1. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
    Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
    Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
    Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
    Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Rabinowitz J; Lichtenberg P; Kaplan Z
    Schizophr Res; 2000 Dec; 46(2-3):91-6. PubMed ID: 11120420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Jerrell JM
    Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antipsychotic drugs produce better outcomes.
    Healthc Benchmarks; 1997 Oct; 4(10):142-4. PubMed ID: 10173374
    [No Abstract]   [Full Text] [Related]  

  • 7. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and guidelines for the inpatient treatment of acute psychosis.
    Feifel D
    J Clin Psychiatry; 2000; 61 Suppl 14():27-32. PubMed ID: 11154014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 10():52-60. PubMed ID: 10340688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics.
    Ismail MS; Dagerman K; Tariot PN; Abbott S; Kavanagh S; Schneider LS
    Curr Alzheimer Res; 2007 Jul; 4(3):325-35. PubMed ID: 17627490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 14. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 15. Liquid risperidone in the treatment of psychotic agitation.
    Tsai C; Puzantian T
    CNS Drugs; 2002; 16(11):777; author reply 778. PubMed ID: 12383033
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical antipsychotics in Parkinson-sensitive populations.
    Friedman JH; Fernandez HH
    J Geriatr Psychiatry Neurol; 2002; 15(3):156-70. PubMed ID: 12230086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
    Olson DA; Ingram W; Mann JR
    J Clin Psychopharmacol; 2002 Oct; 22(5):529-30. PubMed ID: 12352281
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
    Rosenheck RA; Leslie DL; Sindelar JL; Miller EA; Tariot PN; Dagerman KS; Davis SM; Lebowitz BD; Rabins P; Hsiao JK; Lieberman JA; Schneider LS;
    Arch Gen Psychiatry; 2007 Nov; 64(11):1259-68. PubMed ID: 17984395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of psychosis in the elderly: a critical review.
    Hoeh N; Gyulai L; Weintraub D; Streim J
    J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):213-8. PubMed ID: 14653429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
    Schatz RA
    Ann Pharmacother; 2003 Sep; 37(9):1321-4. PubMed ID: 12921516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.